AT&T Inc (T): Yes it is, been watching it for a bit. N...

MegaCentaur44 · 2024-11-16T19:16:23.2630000Z

Yes it is, been watching it for a bit. Nice price movement, analyst estimates of $30, nice divy.

Play Episode

7min

Proactive - Interviews for investors

Clinical study SKNJCT-003 shows positive trends as company advances skin cancer research in UAE

Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to share updates on the ongoing SKNJCT-003 clinical study, which is being conducted at nine sites across the United States and aims to randomize 60 patients. An interim analysis conducted after enrolling more than half of the targeted participants has shown encouraging results. The study reports a clinical clearance rate exceeding 60%, with the investigational therapy demonstrating strong tolerability across both tested dosage levels. Notably, no dose-limiting toxicities (DLTs) or serious adverse events (SAEs) have been observed, and there have been no systemic effects or clinically significant abnormalities in laboratory results, ECGs, vital signs, or physical exams. These promising findings will be submitted to the U.S. Food and Drug Administration (FDA) as part of a Type C meeting request in Q2 2025. In parallel, the company is advancing its clinical initiatives for non-invasive basal cell carcinoma treatment with a newly proposed study. This randomized, double-blind, placebo-controlled, multi-center trial has been submitted for approval to the UAE Department of Health. The study aims to enroll up to 36 patients at prominent medical institutions, including Cleveland Clinic Abu Dhabi, Sheikh Shakbout Medical City, Burjeel Medical City, and the American Hospital of Dubai. Participants will be assigned in a 1:1:1 ratio to receive either a placebo or one of two dosage levels of the experimental treatment. This expansion into the UAE represents a significant step forward in the company’s mission to develop innovative, non-invasive therapies for skin cancer, broadening its global clinical footprint and reinforcing its commitment to advancing patient care. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch

Proactive - Interviews for investors

Pantheon Resources charts new course with leadership transition naming new CEO

Pantheon Resources is entering a pivotal phase as it refines its strategic direction under new leadership. Executive Chairman David Hobbs and newly appointed CEO Max Easley recently spoke with Steve Darling from Proactive, offering insights into the company’s transition and future plans. Hobbs, who is shifting from executive to non-executive chairman, expressed deep appreciation for Jay Cheatham’s 17 years of dedicated service to the company. Meanwhile, Easley, a seasoned industry veteran with over 30 years of experience at BP, Apache and PETRONAS, conveyed his excitement about leading Pantheon Resources at such a critical juncture. A native of Alaska, Easley is particularly drawn to the opportunity to develop Pantheon’s substantial assets in his home state. “Two billion barrels in my own backyard. It’s amazing,” he remarked, underscoring his confidence in the company’s potential. His extensive expertise in both conventional and unconventional oil positions him well to steer the company through its next phase of growth. Looking ahead, Hobbs outlined key milestones for Pantheon and an anticipated surge in company updates. The company’s Annual General Meeting (AGM) is scheduled for March 12, and stakeholders can expect a steady flow of developments. He emphasized the significant progress made over the past 18 months, from securing a path to financing through the agreement with ADC to advancing the Megrez well. As Pantheon transitions from exploration to production, Easley assured investors that momentum is building. “Expect activity followed by good results,” he said, signalling confidence in the company’s trajectory. With strong leadership and a clear strategy, Pantheon Resources is poised for a dynamic and productive year ahead. #proactiveinvestors #pantheonresourcesplc #mining #lse #panr #pthrf #MaxEasley #DavidHobbs #OilAndGas #AlaskaEnergy #CEOInterview #OilProduction #InvestorNews #EnergySector #ProactiveInvestors

Proactive - Interviews for investors

BioHarvest Sciences achieves breakthrough in Liver health with Olive Cell compound

BioHarvest Sciences has announced a significant advancement in liver health research, with new in vitro test results demonstrating the efficacy of its proprietary Olive Cell compound in reducing fat accumulation in human liver cells. CEO Ilan Sobel shared the news with Steve Darling from Proactive, highlighting the compound’s potential in addressing non-alcoholic fatty liver disease (NAFLD)—a condition that affects 30–40% of U.S. adults and currently has limited FDA-approved treatment options. The latest studies revealed that the Olive Cell compound mitigated fat accumulation in both a liver steatosis model and experimental models of liver fibrosis. Additionally, it reduced collagen type 1 levels in XL-2 cells, a key marker of fibrosis progression, further reinforcing its therapeutic potential. BioHarvest attributes these promising results to the compound’s high levels of Verbascoside, a bioactive polyphenol with anti-inflammatory and antioxidant properties. Looking ahead, the company plans to conduct further studies in 2025, with the goal of launching Olive Cell as a nutraceutical product in 2026. Meanwhile, BioHarvest is also exploring pharmaceutical partnerships to bring the compound to market through a CDMO (Contract Development and Manufacturing Organization) model. With these groundbreaking findings, BioHarvest Sciences is positioning itself at the forefront of liver health innovation, offering a potential new solution for millions affected by NAFLD and liver fibrosis. #proactivinvestors #nasdaq #bhst #pharma #biotech #hearthealth #fattyliverdisease #BioHarvestSciences, #IlanSobel, #RevenueGrowth, #NasdaqListing, #IlanSobel #VINIA #HealthTech #Biotech LiverHealth #OliveCell #Verbascoside #NonAlcoholicFattyLiver #SupplementScience #HealthInnovation

Proactive - Interviews for investors

Europa Oil & Gas CEO on Cloughton planning application and community engagement

Europa Oil & Gas (Holdings) Plc (AIM:EOG) CEO Will Holland talked with Proactive's Stephen Gunnion about the company's submission of a planning application for the Cloughton appraisal well in Yorkshire. The application seeks approval to drill and test a gas field originally discovered in 1986. Holland explained that advancements in technology and improved gas prices now make it viable to extract gas at commercial rates. The appraisal well will determine the feasibility of full-field development. He also discussed the launch of a dedicated community engagement website, designed to provide local stakeholders with transparent information, including independent environmental and regulatory reports. Holland emphasised that the project follows strict UK regulations and aims to minimise environmental impact. Addressing concerns, he clarified that fracking is not involved, citing confirmation from Energy Minister Michael Shanks. He also noted that increased heavy goods vehicle (HGV) traffic would be minimal, at around 1% during operations. Holland stressed the project's potential benefits, including job creation and reducing the UK's reliance on imported liquefied natural gas (LNG). “If you're concerned about the environment, you should be supporting domestic gas production. And that's exactly what this is,” he stated. For more interviews with industry leaders, visit Proactive’s YouTube channel. Don't forget to like this video, subscribe, and turn on notifications for updates! #EuropaOilAndGas #EnergySecurity #NaturalGas #UKGas #CloughtonWell #EnergyTransition #Investing #OilAndGas #SustainableEnergy #LNG

Followers	0
Posts	1
Boards Moderated	0
Alias Born	10/09/2024

Volume:	35,311,000
Day Range:	26.54 - 27.21
Bid:
Ask:
Last Trade Time:	7:59:30 PM EST
Total Trades:	161,177

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

T Detailed Quote

Recent T News

More T News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent T News

Go Ad-Free